ProBio is a global contract development and manufacturing organisation (CDMO) dedicated to providing tailored solutions for biologics and advanced therapies.

Founded in 2020, ProBio delivers a comprehensive range of services to support the development and manufacturing of complex biologics, including plasmid DNA and viral vectors. The company’s expertise spans across the full lifecycle of biopharmaceutical products, from pre-clinical through commercial stages. ProBio operates state-of-the-art manufacturing facilities, including its U.S. hub for plasmid DNA and viral vector production in Hopewell, New Jersey. Their commitment to customer-centric solutions has earned them a proven track record, supporting over 108 Investigational New Drug (IND) clearances globally.

Key Products and Services:

• Plasmid DNA production
• Viral vector production
• Biologics manufacturing
• Process development
• cGMP manufacturing for biologics and advanced therapies
• End-to-end contract development and manufacturing services

ProBio’s vision is to empower biopharma companies to deliver life-changing therapies through innovative, reliable, and scalable solutions. With a focus on quality, collaboration, and continuous improvement, ProBio is well-positioned to support the evolving needs of the global biopharmaceutical industry.